公 司 研 究 九强生物(300406) 昨收盘:18.05 | --- | --- | --- | --- | |-------|----------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------ ...

601.29644.85 723.60 0% 2% 4% 6% 8% 10% 12% 14% 0 100 200 300 400 500 600 700 800 2021 2022 2023 收入 YOY 来源：公司年报，中泰证券研究所 图表 9：子公司迈新生物整合后收入快速增长（百万元） 国药合作进展顺利，2024 年更多协同有望陆续落地。公司自引入国药为 公司第一大股东以来，不断加快与国药集团的协同整合，2023 年引进国 请务必阅读正文之后的重要声明部分 - 5 - 公司点评 药系高管，完成事业部改制，从研发、生产、质控、管理等多维度实现 效能提升；2024 年初增资 FISH 检验细分龙头龙进生物，进一步提升在 病理市场的综合竞争力；与此同时大股东国药也持续增持公司股份，对 公司认可度不断提升，公司积极拥抱战略变化、主动作为，未来有望持 续与国药在产品研发、投资并购、营销渠道等领域落地更多合作，逐步 成长为具有央企品质、国药品牌的综合型 IVD 企业。 请务必阅读正文之后的重要声明部分 - 6 - 公司点评 | --- | --- | --- | --- | --- | --- | --- | --- ...

证券代码：300406 证券简称：九强生物 公告编号：2024-028 债券代码：123150 债券简称：九强转债 北京九强生物技术股份有限公司 关于2024年第一季度可转换公司债券转股情况的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 特别提示： 1、"九强转债"（债券代码：123150）的转股期限为 2023 年 1 月 6 日至 2028 年 6 月 29 日；最新有效的转股价格为 17.55 元/股。 2、2024 年第一季度，共有 110 张"九强转债"（票面金额共计 11,000 元人 民币）完成转股，合计转成 625 股"九强生物"（股票代码：300406）股票。 3、截至 2024 年第一季度末，公司剩余可转债为 11,210,259 张，剩余票面 总金额为 1,121,025,900 元人民币。 根据《深圳证券交易所创业板股票上市规则》和《深圳证券交易所上市公司 自律监管指引第 15 号——可转换公司债券》的有关规定，北京九强生物技术股 份有限公司（以下简称"公司"）现将 2024 年第一季度可转换公司债券转股及 公司总股本变化情况公 ...

关于回购公司股份的进展公告 证券代码：300406 证券简称：九强生物 公告编号：2024-027 债券代码：123150 债券简称：九强转债 北京九强生物技术股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 北京九强生物技术股份有限公司（以下简称"公司"） 于 2023 年 7 月 21 日召开的第四届董事会第三十三次（临时）会议审议通过了《关于回购公 司股份方案的议案》，独立董事已对本次回购事项发表了同意的独立意见。 同意公司使用自有资金以集中竞价交易的方式回购部分公司股份，回购股份 后续用于实施股权激励或员工持股计划。本次用于回购的资金总额不低于人 民币 4,000 万元且不超过人民币 8,000 万元，本次回购价格不超过人民币 30 元/股。具体回购股份的数量以回购期满时实际回购的股份数量为准。本次回 购股份的实施期限为自公司董事会审议通过本次回购方案之日起 12 个月内。 公司于 2023 年 7 月 21 日披露了《关于回购公司股份方案的公告》（公告编 号：2023-070）、《回购报告书》（公告编号：2023-071）；公司于 202 ...

2024 年 3 月 31 日 23Q4 业绩亮眼，国药赋能持续推进 点评： 公司各项业务恢复，经营发展回暖显著：公司 2023 年营业收入 17.42 亿元 （YOY+15.27%），归母净利润 5.24 亿元（YOY+34.60%），扣非归母净利润 5.11 亿元（YOY+32.51%）。23 年全国医疗机构正常运行，公司业务恢复至正 常水平，产品覆盖生化免疫、血凝、血型、病理诊断和精准诊断大类，销售收入 和利润均有所增长。 研发投入持续增加，化学发光赛道新布局：公司 2023 年年度研发投入 1.63 亿 元，同比增长 18.73%；报告期内共获得专利证书 52 个，医疗器械注册证 34 个。 化学发光是 IVD 中公认的优质赛道，近年来政策扶持显著，国产替代趋势明显。 23Q4 公司全自动化学发光免疫分析仪 Gi1600、Gi2000、Gi9000 先后获批，标 志着公司正式进入化学发光领域，有助于公司通过多元化布局的协同效应保障公 司稳健可持续发展。 国药赋能潜力巨大，产品分销助力出海：截至 2023 年末，中国医药投资持有公 司 16.63%的股份，为公司第一大股东。23 年 9 月，梁红军先生首 ...

Product Development and Innovation - The company launched several new antibody reagents for immunohistochemistry, including CA 125, MSH6, and Galectin-3, marking their first introduction during the reporting period[1]. - The new antibody reagents are designed to provide diagnostic assistance to physicians based on routine staining methods[1]. - The company has received 510(k) exemptions for all newly launched antibody reagents, indicating compliance with regulatory standards[1]. - The focus on long-term development for these products suggests a strategic commitment to enhancing diagnostic capabilities in the healthcare sector[1]. - The introduction of these products is expected to expand the company's market presence and enhance its competitive edge in the biotechnology field[1]. - The company is actively collaborating with Fuzhou Maixin Biotechnology Development Co., Ltd. for the development of these new products[1]. - The antibody reagents cover a wide range of applications, indicating a comprehensive approach to immunohistochemistry diagnostics[1]. - The company aims to leverage these new products to drive future revenue growth and market expansion[1]. - The ongoing development of innovative diagnostic tools aligns with the company's strategic vision for long-term sustainability and growth[1]. - The successful launch of these products may lead to increased market share and improved financial performance in the upcoming fiscal periods[1]. - The company has launched 47 medical device registration certificates for new products, including mid-speed and ultra-high-speed automated chemiluminescence analyzers[11]. - The company has developed over 20 reference methods in its reference laboratory, focusing on enzymology, metabolites, proteins, and hormones[8]. - The company is focused on developing high clinical value testing reagents and aims to achieve full coverage of laboratory testing projects[58]. - The company is actively involved in the development of new products, including the vWFAg and anti-Xa reagent kits, which are currently in collaborative research projects with universities[123]. - The company has initiated a national key research and development project focused on the clinical application value of urine PSA for prostate hyperplasia, which started in April 2023[123]. Market Performance and Financials - The company reported a significant increase in revenue, achieving a total of 1.2 billion RMB in 2023, representing a year-on-year growth of 15%[114]. - The net profit margin increased to 30.07% in 2023, up from 25.76% in 2022[25]. - The overseas sales revenue grew by 7.87% year-on-year, reflecting the company's expanded international market influence[22]. - The production volume of in vitro diagnostic reagents increased by 25.25% year-on-year, reflecting strong market demand[33]. - The company reported a revenue increase of 15% year-over-year, reaching CNY 1.2 billion in 2023[170]. - New product launches contributed to 30% of total revenue, with three major products introduced in Q3 2023[170]. - Market expansion efforts led to a 40% increase in international sales, now accounting for 15% of total revenue[170]. - The company provided a forward guidance of 10% revenue growth for the next fiscal year, projecting revenues of CNY 1.32 billion[170]. Research and Development - The company's R&D investment for 2023 was ¥162,898,782.94, an increase of 18.73% compared to 2022[13]. - The company's R&D investment for 2023 amounted to ¥162,898,782.94, representing 9.35% of its operating revenue, an increase from 9.08% in 2022 and 7.94% in 2021[42]. - The R&D investment increased by 20%, amounting to CNY 200 million, focusing on innovative biotechnologies[170]. - The number of R&D personnel increased by 18.12% to 339 in 2023, with a notable rise in the number of bachelor's degree holders[40]. Strategic Partnerships and Collaborations - The company has established strategic partnerships with major firms such as Abbott, Roche, and Hitachi since 2013, enhancing its market position in the IVD sector[7]. - The company is actively collaborating with Fuzhou Maixin Biotechnology Development Co., Ltd. for the development of these new products[1]. - A new strategic partnership was established with a leading biotech firm to co-develop advanced therapies[170]. Governance and Compliance - The company has established a governance structure with a board of directors, supervisory board, and management team to ensure effective decision-making and oversight[106]. - The board of directors consists of 9 members, including 1 chairman and 1 vice chairman, overseeing major investment and strategic decisions[106]. - The supervisory board, composed of 3 members, is responsible for monitoring the actions of directors and management[106]. - The company has implemented a robust governance structure, ensuring compliance with legal requirements and enhancing operational efficiency[117]. - The internal control evaluation report indicates that 100% of the assets and operating income of the evaluated units are included in the consolidated financial statements[138]. - There were no significant defects identified in financial reporting or non-financial reporting during the evaluation period[138]. - The internal control measures established by the company include transaction authorization control, responsibility division control, and budget control, ensuring compliance in business operations[162]. - The company has not identified any significant deficiencies in its internal control during the reporting period[142]. Corporate Social Responsibility - The company has maintained a strong commitment to corporate social responsibility, being recognized as one of the "Top 500 Charitable Enterprises in China" in 2022[125]. - The company is committed to increasing its investment in charitable activities and giving back to society[153]. - The company emphasizes sustainable development, aiming to align short-term and long-term interests while enhancing its social contributions[156]. - The company aims to create more value for society through its charitable actions and contributions[153]. - The company has focused on employee welfare, providing competitive salaries and benefits, and ensuring a harmonious labor relationship[118]. - The company emphasizes environmental protection and sustainability, promoting energy-saving practices and raising awareness among employees[122]. Human Resources and Employee Management - The total number of employees at the end of the reporting period was 1,031, including 619 at the parent company and 412 at major subsidiaries[180]. - The company intends to optimize personnel selection and enhance employee training to build a highly skilled workforce for future growth[81]. - The company has established a performance management framework to enhance the performance evaluation and incentive mechanisms for senior management[189]. - The company has set up a compensation and assessment committee to oversee the performance evaluation of directors and senior management[189]. Financial Management and Investments - The company reported a net cash flow from investing activities increased by 71.14%, primarily due to the recovery of a large certificate of deposit from Mai Xin[61]. - The company has a total of ¥12,407,332.05 in bank deposits as of December 31, 2023, which are frozen as guarantee deposits[47]. - The company reported an investment amount of 5,500,000.00 CNY for the reporting period, a decrease of 95.98% compared to the previous year's investment of 136,775,000.00 CNY[67]. - The company has proposed a share repurchase plan, detailing the purpose, conditions, and funding sources[194]. - The total pre-tax remuneration for the board of directors and senior management amounted to CNY 1,019.18 million[192]. - The chairman, Zou Zuo Jun, received a pre-tax remuneration of CNY 243.44 million, while Liu Xi, a non-independent director, received CNY 201.78 million[192]. Future Outlook and Strategic Goals - The company aims to solidify its leading position in niche markets while accelerating transformation to build an international, comprehensive medical technology platform[57]. - The company plans to enhance market share by analyzing market conditions and policies, and by implementing a collaborative sales strategy of "instruments + reagents"[59]. - The company will adopt a dual approach of internal growth and external mergers and acquisitions to explore high-demand market areas and enhance its product portfolio[78]. - The management team emphasized a commitment to sustainability, targeting a 30% reduction in operational carbon footprint by 2025[170].

证券代码：300406 证券简称：九强生物 公告编号：2024-021 债券代码：123150 债券简称：九强转债 北京九强生物技术股份有限公司 关于变更注册资本并修订《公司章程》的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 北京九强生物技术股份有限公司于2024年3月29日召开了第五届董事会 第五次会议，审议通过了《关于变更注册资本并修订<公司章程>的议案》。 具体情况如下： | 拟讨论的事项需要独立董事发表意见的，发布股东大 | | | --- | --- | | 会通知或补充通知时应同时披露独立董事的意见及 | | | 理由。 | | | 第五十八条 发出股东大会通知后，无正当理由，股东 | 第六十条 发出股东大会通知后，无正当理由，股东大 | | 大会不应延期或取消，股东大会通知中列明的提案不 | 会不应延期或取消，股东大会通知中列明的提案不应 | | 应取消。一旦出现延期或取消的情形，召集人应当在 | 取消。一旦出现延期或取消的情形，召集人应当在原 | | 原定召开日前至少 2 个工作日通知股东并说明原因。 | 定召开日前至少 2 个工作日 ...

2023 年度独立董事述职报告 北京九强生物技术股份有限公司 2023 年度独立董事述职报告 各位股东及股东代表： 2023 年度独立董事述职报告 作为北京九强生物技术股份有限公司（以下简称"公司"）的独立董事，报告期 内本人任职期间严格按照《中华人民共和国公司法》《中华人民共和国证券法》《上 市公司独立董事管理办法》《上市公司自律监管指引第 2 号——创业板上市公司规范 运作》等法律、法规以及《北京九强生物技术股份有限公司章程》（以下简称"《公 司章程》"）和《北京九强生物技术股份有限公司独立董事工作制度》（以下简称"《独 立董事工作制度》"）的相关规定和要求，本着客观、公正、独立的原则勤勉尽责、 独立履职，及时了解公司的生产经营及发展情况，促进公司规范运作、健康发展，维 护公司、全体股东特别是中小股东的利益。现将 2023 年度工作情况报告如下： 一、公司独立董事基本情况 叶军，1967 年 5 月出生，中国籍，无境外永久居留权，本科。1990 年 7 月毕业 于西安电子科技大学；1990 年 8 月-1992 年 6 月供职于电子部六所，任助理工程师； 1992 年 7 月-1994 年 4 月供职于电 ...

2023 年度独立董事述职报告 北京九强生物技术股份有限公司 2023 年度独立董事述职报告 各位股东及股东代表： 作为北京九强生物技术股份有限公司（以下简称"公司"）的独立董事，报告期 内本人任职期间严格按照《中华人民共和国公司法》《中华人民共和国证券法》《上 市公司独立董事管理办法》《上市公司自律监管指引第 2 号——创业板上市公司规范 运作》等法律、法规以及《北京九强生物技术股份有限公司章程》（以下简称"《公 司章程》"）和《北京九强生物技术股份有限公司独立董事工作制度》（以下简称"《独 立董事工作制度》"）的相关规定和要求，本着客观、公正、独立的原则勤勉尽责、 独立履职，及时了解公司的生产经营及发展情况，促进公司规范运作、健康发展，维 护公司、全体股东特别是中小股东的利益。现将 2023 年度工作情况报告如下： 一、公司独立董事基本情况 杨建平，1955 年 10 月出生，中国籍，无境外永久居留权，硕士。2008 年 10 月- 2020 年 10 月任北京中海联行投资顾问有限公司董事长；2010 年 5 月-2020 年 5 月任 北京中海锐智科技有限公司董事长；2014 年 10 月-2020 年 ...

北京九强生物技术股份有限公司 Beijing Strong Biotechnologies, Inc. 章 程 二零二四年三月 1 | 目录 | | --- | | 第一章 | 总则 | 3 | | --- | --- | --- | | 第二章 | 经营宗旨和范围 | 4 | | 第三章 | 股份 | 4 | | | 第一节 股份发行 4 | | | | 第二节 股份增减和回购 5 | | | | 第三节 股份转让 7 | | | 第四章 | 股东和股东大会 | 7 | | | 第一节 股东 8 | | | | 第二节 股东大会的一般规定 10 | | | | 第三节 股东大会的召集 14 | | | | 第四节 股东大会的提案与通知 16 | | | | 第五节 股东大会的召开 17 | | | | 第六节 股东大会的表决和决议 21 | | | 第五章 | 董事会 | 25 | | | 第一节 董事 25 | | | | 第二节 董事会 29 | | | 第六章 | 总经理及其他高级管理人员 | 35 | | 第七章 | 监事会 | 37 | | | 第一节 监事 37 | | | | 第二节 监事会 ...